This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Vifor Pharma Management

Management criteria checks 2/4

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	6.9yrs
Board average tenure	3.6yrs

Recent management updates

Recent updates

CEO

Vifor Pharma has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Alexandros Sigalas	Acting CFO & Head of IT & Administration	6.9yrs	no data	no data
Frederic Zwahlen	Head of Technical Operations	less than a year	no data	no data
Julien Vignot	Head of Investor Relations & Treasury	5.9yrs	no data	no data
Oliver Kronenberg	Group General Counsel	8.9yrs	no data	no data
Nathalie Ponnier	Global Head Corporate Communications	no data	no data	no data
Michael Puri	Chief Human Resources Officer	7.6yrs	no data	0.014% € 1.5m
Christoph Springer	Chief Strategy Officer	6.9yrs	no data	0.052% € 5.3m
Thomas Kaspar	Head of Global Quality Management	11.9yrs	no data	no data
Thierry Teil	Head of Global Medical Affairs	6.9yrs	no data	no data
Carolina Ponchione	Head of Executive Search & Employer Branding	4.9yrs	no data	no data
Barbara Angehrn	Chief Business Officer	4.1yrs	no data	0.0027% € 273.2k
Antonio Jordao	Regional Head of Southern Europe	no data	no data	no data

6.9yrs

Average Tenure

53yo

Average Age

Experienced Management: G2AB's management team is seasoned and experienced (6.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jacques Theurillat	Independent Chairman of the Board	4.6yrs	CHF 1.20m	0.0066% € 673.3k
Asa Riisberg	Independent Director	1.6yrs	CHF 133.00k	no data
Etienne Jornod	Honorary Chairman	2.6yrs	CHF 3.33m	no data
Alexandre Lebeaut	Independent Director	1.6yrs	CHF 117.00k	no data
Michel Burnier	Independent Director	12.9yrs	CHF 231.00k	0.017% € 1.7m
Romeo Cerutti	Independent Vice Chairman & Lead Independent Director	7.9yrs	CHF 326.00k	0.015% € 1.5m
Kim Stratton	Independent Director	3.6yrs	CHF 211.00k	0.0019% € 188.9k
Susan Mahony	Independent Director	3.6yrs	CHF 260.00k	0.0022% € 222.4k

3.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: G2AB's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/12/26 13:43
End of Day Share Price	2022/12/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vifor Pharma AG is covered by 22 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Armelle Moulin	AlphaValue
Volker Bosse	Baader Helvea Equity Research
Jean-Philippe Bertschy	Bank Vontobel AG

This company listing is no longer active

Vifor Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Announces Board Changes

Recent updates

Cancellation of Remaining Publicly Held Registered Shares of Vifor Pharma

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

Vifor Pharma Announces Board Changes

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources